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The rise in drug-related mortality rates in the United States has been especially 
concerning1. Ohio is among the top states experiencing an increase in mid-life mortality with one 
driving factor being the opioid crisis1. In the last two decades, the overall drug overdose rate in 
Ohio increased nine-fold compared to the national average increase of three-fold2. In 2018, Ohio 
was among the top 5 states for the highest mortality rates due to drug overdoses with 35.9 deaths 
per 100,000, compared to a national average of 20.7 per 100,000 population3. 
The severity of the opioid crisis has pushed local and state governments to expand 
Medication Assisted Treatment with evidence showing it may reduce the likelihood of overdose 
deaths by up to three-fold4. Medication Assisted Treatment (MAT) is an evidence-based 
intervention that uses medications, such as methadone, buprenorphine, and naltrexone, alongside 
counseling and behavioral therapies to treat substance use disorders, including opioid and 
alcoholic use disorders3,5. Numerous studies indicate that MAT has limited the occurrence of 
opioid related deaths and overdoses, while reducing cravings and stabilizing physical 
dependency for patients struggling with addiction5,6,7. 
Only authorized treatment programs and/or providers can deliver MAT to patients. There 
are several steps required in order for opioid treatment programs (OTPs) to receive the 
authorization necessary to administer MAT. These programs must first receive accreditation 
from the Substance Abuse and Mental Health Services Administration (SAMHSA) and are 
further certified by SAMHSA’s Division of Pharmacologic Therapies to conform to federal 
regulations. The Drug Enforcement Agency and the Department of Health and Human Services 
help SAMHSA in overseeing the medications provided in MAT at the OTP8. Only OTPs are 
allowed to prescribe the drug methadone. OTPs have the authority to prescribe buprenorphine or 
naltrexone without being required to obtain a SAMHSA waiver, which is a step required of 
clinicians who practice outside these programs9. Patients in OTPs who are receiving MAT must 
undergo additional counseling, and they are offered other services to help in their recovery10.   
Under the Drug Addiction Treatment Act of 2000 (DATA 2000), additional authorized 
clinicians who practice outside of opioid treatment programs received legal authority to prescribe 
MAT with buprenorphine or naltrexone if obtaining a DATA waiver11. For a practitioner to 
obtain a waiver to practice opioid dependency treatment, they must apply to the Center for 
Substance Abuse Treatment (CSAT) under SAMHSA. Qualified clinicians must satisfy certain 
requirements set by SAMHSA, including undergoing certification training before obtaining a 
DATA waiver to offer MAT11. Afterwards, clinicians must upload a certificate showing evidence 
of training before gaining formal authorization to prescribe or dispense buprenorphine. In order 
to begin treating up to 100 patients in their first year, the qualifying clinicians must either hold a 
board certification in addiction medicine or addiction psychiatry. Other physicians who are not in 
addiction medicine may also provide MAT if they reside in a qualified practice setting12. These 
settings may include, but are not limited to, a physician’s office, community hospital, health 
department, or correctional facility13.  
When the DATA of 2000 was first passed, only physicians were eligible for the DATA 
waiver. However, the DATA waiver was later extended to other qualified clinicians under the 
Comprehensive Addiction and Recovery Act of 2016, which enabled nurse practitioners and 
physician assistants to also provide MAT14. Between 2017 and 2018, buprenorphine dispensing 
rates have increased, suggesting that an additional supply of clinicians has enabled greater 
prescribing capacity for those with opioid use disorder15.  
Although more efforts have been implemented to expand clinicians’ eligibility to provide 
MAT, there still exists a shortage in the availability of providers in many areas. In 2017, 
approximately 46.4% of all US counties lacked an authorized clinician to prescribe MATs for 
opioid use disorders, a situation even worse in rural counties (71.6%)16. Over 30 million 
Americans live in counties without access to a provider for buprenorphine treatment17. While the 
number of waivered providers has steadily increased in recent years, over 30% of U.S. counties 
still do not have a single DATA waived provider18. Among those who do have a waiver, over 
40% are psychiatrists, and slightly more than a third include primary care specialties of family or 
internal medicine17.  However, only 3% of all primary care physicians and 16% of psychiatrists 
have obtained this waiver, and they are more likely to practice in urban settings17. An even more 
concerning realization is the large shortage of psychiatrists and primary care specialties whom 
are among the most common to provide MAT. By 2024, the psychiatrist workforce could range 
from a shortage of 14,280 to 31,091 psychiatrists19. By 2035, there will be an estimated shortage 
of 44,000 primary care physicians20. In a public policy statement, the American Society of 
Addiction Medicine vocalized this concern when stating that “public health demands of 
substance use and addiction are so extensive that specialists in addiction medicine will never be 
able to meet all the demand for health care services of this population.”21 Therefore, the large 
shortage in waivered providers and even larger shortage among the providers who most likely 
administer MAT, demonstrates the urgency to examine this issue further in one of the most 
vulnerable states to the opioid crisis: Ohio. 
The clinician shortage of eligible providers to treat opioid use disorder also remains an 
issue with opioid treatment programs. Almost one-third of U.S counties do not have any OUD 
treatment programs22. Among private treatment programs, less than a half offer MAT, and only 
one-third of opioid dependent patients actually received the treatment23. Overall, many states 
struggle in providing sufficient treatment capacity for all patient’s suffering from opioid use 
disorder24. 
Although extensive literature exists presenting the nationwide issue of insufficient 
treatment capacity, few studies focus specifically on the burden in Ohio despite its acute opioid 
crisis. Some evidence has been suggestive of accessibility issues in Ohio with 20% of office-
based treatment clinicians not actively prescribing and a half of them denying insurance for their 
services25. In contrast, among Ohio specialty treatment programs, almost half of them reported 
insufficient prescribing capacity26. And, among those with insufficient prescribing capacity, half 
of them had to turn away patients from buprenorphine therapy26. This suggests a potential 
maldistribution of authorized MAT providers that do not match the treatment needs.  
Even if all providers operate at full-capacity, Ohio may only be able to treat 20-40% of 
the entire population abusing opioids or who have developed dependence2. Given the current 
opioid crisis, an inefficient prescriber capacity to deal with this large population raises serious 
concerns. This demonstrates the importance of gathering knowledge to evaluate how the current 
supply of DATA providers and OTPs in Ohio meet drug treatment needs. Our study aims to 
characterize the co-locations of DATA providers and OTPs with the concentrations of drug 
overdose deaths in Ohio to understand whether potential capacity is available to meet the needs 
of reducing opioid mortality. The high number of overdose deaths in Ohio emphasizes the 
importance of this study, which is among the few known to look at both the supply of waivered 
providers and opioid treatment programs. Overall, this information is critical for policy decisions 
that impact the allocation of state resources, workforce planning, and targeted interventions to 




Clinician waiver data was obtained from SAMHSA to analyze Buprenorphine 
Practitioners in Ohio in 2019. Because clinicians have to obtain a certificate from SAMHSA to 
prescribe MAT, SAMHSA continuously collects and track clinicians in the Buprenorphine 
Waiver Registration Database and makes the data public. I examined this database with 
geographic location information. For each county, the database contains the detailed information 
about practitioners with a waiver, including medical doctors, physician assistants, osteopathic 
doctors, and nurse practitioners, as well as the name, city, address, and telephone number of each 
provider. Providers whose addresses were listed but did not specify their county classifications, 
were manually tracked via ZIP codes and street addresses to identify their county of residence. 
Additionally, a list of opioid treatment programs in Ohio were obtained from SAMHSA’s 
opioid treatment program directory. This included accredited programs earning SAMHSA 
certification, as well as provisional programs still undergoing the full accreditation process27,28,29. 
Physicians within OTPs should have completed an accredited residency program and hold at 
least 1 year of experience in addiction medicine or psychiatry, while completing training of all 
the FDA approved medications for opioid use disorder treatment. Multiple providers can practice 
within an OTP program without having to separately obtain a DATA waiver. However, the OTP 
must designate between patients who are cared for by a waivered physician under the DATA 
2000, and physicians who are authorized to prescribe MAT via other credentials30.   
County-level opioid overdose metrics came from the County Health Rankings and 
Roadmaps program that compiled drug overdose deaths from the Center of Disease Control’s 
mortality data31. The number of drug overdose deaths and drug overdose death rates in each 
county were used from 2015-2017, which is based off of a three-year average, the most updated 
data available during the study period. Additionally, the poverty rate for each county was 
obtained by the U.S Census Bureau for the period 201932. It is the percent of county population 
in poverty as defined by the federal thresholds in 2019. Additionally, the population numbers in 
each county were taken from the U.S Census Bureau from 2018.  
Study Sample 
 A total of 2,147 DATA registered providers were included in the analysis. There were 
259 providers in the DATA registry with missing specialties. They were included in the analysis 
of total waivered practitioners for each county. Providers with missing specialty can represent 
any provider type. We focused on physicians, nurse practitioners (NP) and physician assistants 
(PA). Medical and osteopathic doctors were combined into one group to represent total 
physicians. 
Moreover, practitioners who were registered under more than one address, such as those 
practicing in more than one city within the same Ohio county or reported more than once under 
the same address, were not duplicated and were treated as one provider. For practitioners who 
practiced in more than one county, they were counted as a separate provider under each county. 
Additionally, 4 townships in Ohio that were reported with registered providers— Boyd, Cook, 
Fresno, and Tulsa townships, were regrouped into their respective counties for consistency. Out 
of 88 Ohio counties, 9 did not report any waivered providers: Ashland, Champaign, Harrison, 
Holmes, Monroe, Noble, Ottawa, Paulding, and Preble. The final analytic sample included 2,075 




Waivered provider density was defined as the number of waivered providers per 100,000 
population in a county. We included a provider density measure for both total DATA providers, 
as well as for each of the three provider types above (physician, nurse practitioner, and physician 
assistant). Opioid treatment program density was defined as the number of opioid treatment 
programs per 100,000 population in a county. The opioid burden is based off of drug overdose 
mortality rates, which is defined as the number of drug poisoning deaths per 100,000 population. 
The drug poisoning deaths in the numerator were represented by deaths from accidental, 
incidental, and undetermined drug poisoning for the aggregate annual population over the three-
year period from 2015-2017. The absolute number of drug overdose deaths were also utilized as 
a measure of the opioid burden during robustness analyses. Four counties did not report any drug 
overdose deaths: Monroe, Morgan, Paulding, and Vinton and were coded as 0 in my analyses.   
Statistical Analysis 
We conducted a cross-sectional analysis at the county level to examine the correlation 
between DATA-waived providers and opioid mortality rates, and opioid treatment programs and 
opioid mortality rates, respectively. We first described the distributions of waivered provider 
types across all Ohio counties. The waivered provider sample was further examined to identify 
the number of providers who offered MAT in multiple counties across Ohio. The waivered 
provider density was calculated for each county and compiled into a histogram distribution to 
compare density variation across counties.  
 To gauge whether potential MAT treatment capacity matches the local medical needs, we 
employed a series of hypothesis tests between measures of the supply of waivered providers and 
OTPs, and measures of opioid burden and poverty. Pearson correlation tests were applied to test 
the correlations between waivered provider density, poverty rate, and opioid overdose rates. 
Pearson correlation tests were further applied to test the correlations between opioid treatment 
programs, poverty rate, and opioid overdose rates.  Strength thresholds picked for the Pearson 
correlational coefficient (R) are based on a scale commonly cited in the social sciences, which 
was established by Dancey and Reidy33. The following strengths for R are 0 = zero correlation, 
(+/-) 0.1-0.3 are weak correlations, (+/-) 0.4-0.6 are moderate correlations, (+/-) 0.7-0.9 are 
strong correlations, and (+/-) 1 is a perfect correlation.   
A two-sample unpaired t-test compared the difference in means for OTP density for the 
counties with the five highest and lowest overdose rates compared to the average OTP density 
among all other counties. For the robustness analysis, I used a two-sample unpaired t-test to 
compare poverty rates between counties having the highest and lowest overdose rates. Further 
sensitivity tests were conducted to describe alternative versions of opioid burden using the 
absolute number of opioid deaths.  A 95% confidence interval was used for all tests.   
Results  
Figure 1 presents the total sum of all waivered providers registered in the Buprenorphine 
Waiver database by provider type across all counties. Most of the waivered practitioners in Ohio 
were physicians (57%). Twenty-seven percent of waivered providers were NPs (27%), followed 
by PAs (4%). Twelve percent of the practitioners in the database did not specify what type of 
provider they were, although they did have waivers to prescribe MAT treatment. Only 34% of 
counties contained opioid treatment programs. There is a total of 80 opioid treatment programs 
in Ohio. The maximum number of opioid treatment programs observed in a single county was 
11, which was seen for Hamilton County. 
 Table 1 exhibits the number of waivered providers who practiced in more than one 
county. 50 providers listed in the database practiced in more than one county, based on practice 
addresses in the registry. Among those, 42 practiced in two counties, and 8 practiced in more 
than two counties. This may indicate that they were serving a bigger geographic region or were 
locating at the county borders.   
Figure 2 displays the distribution of waivered provider densities across Ohio counties. 
The average waivered provider density in a county, including all provider types, was 13.90 per 
100,000 population (SD 9.9; 95% CI 11.7-16.1). The medium was 11.3 per 100,000 among all 
counties. There was a substantial variation in waivered provider density. Waivered provider 
densities ranged from a minimum of 1.89 per 100,000 to a maximum of 47.89 per 100,000 
population (Figure 2). Several counties had over 34.3 per 100,000 waivered physicians. These 
were Allen, Mahoning, Ross, Scioto, and Gallia counties.  
 In Figure 3, a statistically significant positive relationship was observed between the 
density of providers and opioid overdose death rates across Ohio counties (r(76) = .40, P<.001; 
95% CI .19-.57). This effect was moderate. Higher provider densities were correlated with 
higher overdose rates in a county. This may suggest that providers in high need regions are more 
likely to obtain waivers. However, the medium correlation also suggests that waivered providers 
do not necessarily co-locate at where the potential patients are.  
 The correlation between locations of opioid treatment programs and overdose rates were 
further analyzed (Figure 4). A significant, moderate to weak, positive relationship was observed 
between the number of opioid treatment programs and drug overdose rates (r(76)=.39, P <.001; 
95% CI .18-.56). Additionally, poverty rate did not have any significant influence on the 
abundance of opioid treatment programs in counties (P =.18).  
Measures in counties with the highest and lowest overdose rates were examined and 
compared to. Among the counties with the highest overdose burden, poverty rates were higher 
than the average poverty rate among all counties. The average poverty rate for the highest 
overdose counties was 16% (SD 1.62; 95% CI 12.81-11.84), which was higher than the state 
average rate of 12.8% (SD .46; 95% CI 11.84-13.67).  
When comparing the waivered provider rankings for the highest overdose counties, most 
did not place in the upper quartile for the highest densities with the exception of Scioto and 
Montgomery county. This may raise some questions as to whether Clark, Butler, Trumbull and 
Brown counties, counties with the worse overdose death rates, currently have a sufficient supply 
of waivered providers to meet high overdose burdens. Most of these counties had a higher 
proportion of physicians than nurse practitioners and physician assistants, which was consistent 
with the overall sample. Montgomery County had the highest overdose rate in all of Ohio. It 
possessed a provider density of 26.11 per 100,000 population, which was higher compared to the 
sample average of 13.90 per 100,000. Scioto County was considered an outlier among all 88 
counties for its high waivered provider density (Figure 2). All of the highest overdose counties 
contained opioid treatment programs, and most counties with lower overdose death rates do not 
have OTP programs.  
For counties with the lowest overdose burden, the poverty rates were variable. When a 
two-sample unpaired t-test was conducted between low overdose counties and all other counties, 
the mean poverty rates were comparable. The lowest overdose counties had an average poverty 
rate of 14.09% (SD 1.74; 95% CI 10.62-17.56), and all other counties aggregated had an average 
poverty rate of 12.8% (SD 0.53; 95% CI 11.69-13.81). When comparing the waivered provider 
rankings for the lowest overdose counties, most placed in the lower third and fourth quartile for 
the waivered provider densities with the exception of Athens county in the upper quartile. Since 
these counties had small overdose rates, the lower rankings might reflect a smaller urgency for 
waivered providers in these counties. Morgan and Vinton counties had no overdose deaths, and 
these counties had no registered physicians, registered physician assistants, or opioid treatment 
programs. The waivered provider densities of Morgan and Vinton, 6.85 and 7.61 per 100,000 
consecutively, were lower than the sample average of 13.90 per 100,000 population. Athens was 
the only county among those with the lowest overdose deaths that had an opioid treatment 
program (Table 3).  
 When comparing the mean waivered provider densities, the 5 counties with the highest 
overdose rates had much higher mean provider densities (20.50 per 100,000, SD 4.10; 95% CI 
12.32-28.69) than all other counties (13.76 per 100,000, SD 1.24; 95% CI 11.29-16.23). Counties 
with the five lowest overdose rates had on average lower waivered provider densities (9.52 per 
100,000, SD 3.51; 95% CI 2.52-16.51) than all other counties (13.76 per 100,000, SD 1.14; 95% 
CI 11.48-16.03).  
A two-sample unpaired t-test displayed a significant difference in the mean OTP density 
per 100,000 population between the top 5 highest overdose counties and all other counties 
(t(70)= 2.71, P = .009; 95% CI .22-1.43). The high overdose counties had an OTP density of 
1.24 per 100,000 (SD .29; 95% CI .66-1.82), which was much higher than the mean of 0.41 per 
100,000 (SD .09; 95% CI .24-.59) for all other counties. This may suggest that these programs 
concentrate in counties with higher burdens (Table 2). A two-sample unpaired t-test found no 
difference in the mean density of opioid treatment programs for the 5 lowest overdose counties 
compared to all other counties (t(71)= -.71, P=.48; 95% CI -.77-.36). Lastly, a two-sample 
unpaired t-test between the highest and lowest overdose rate counties found no significant 
difference in the means for poverty rate (t(11)=-.47, P =.64; 95% CI -11.10-7.20). Therefore, it is 
likely that poverty did not contribute significantly to any differences seen among the highest and 
lowest overdose counties. 
Robustness Tests 
A sensitivity test was employed to vary overdose death rates with the absolute number of 
overdose deaths to understand if the relationship with total waivered provider density held 
consistent. A significant positive relationship was also found between total waivered provider 
density and the number of overdose deaths across counties (r(76) = .31, P=.006; 95% CI .09-
.50). Although this effect was weaker, a significant correlation further validates a likely positive 
relationship between the supply of waivered providers and opioid burden. 
It is possible that providers sought to practice in regions with a higher population income 
and the areas with high overdose death rates (low incomes) may be impoverished with very few 
providers. Therefore, in Figure 5, we displayed the relationship between poverty rates and 
overdose death rates and found a weak significant, positive relationship (r(76) = .32, P = .004; 
95% CI .11-.50). This indicates that poorer counties were slightly more vulnerable to having a 
higher overdose burden. I also tested the correlation between poverty rate and total waivered 
provider density in Figure 5. This displayed a moderate, positive relationship, indicating that 
providers may be more likely to obtain a waiver in poorer regions, consistent with our earlier 
findings (r(76) = .46, P < .001; 95% CI .26-.62).  
A sensitivity analysis aimed to test the consistency of the relationship between opioid 
treatment programs and opioid burden when substituting overdose rates for the absolute number 
of deaths. A significant positive relationship was observed between the number of opioid 
treatment programs and the number of drug overdoses in a county (r(77)=.86, P <.001; 95% CI 
.78-.91). This effect was strong, and even stronger compared to overdose rates. The correlation 
heavily indicates for more opioid treatment programs to concentrate in counties having the 
largest absolute number of deaths from opioids with a smaller emphasis on the total county 
population.  
Discussion 
The opioid crisis has significantly impacted Ohioans with Ohio standing among the top 
five states for the highest opioid mortality rates. This has important implications for estimating if 
Ohio has sufficient treatment capacity to reduce deaths related to opioids. Additionally, with 
newer evidence that many addiction treatment centers are possibly facing financial collapse34, 
and other estimates that Ohio may only be able to treat 20-40% of the entire population abusing 
opioids or who have developed dependence2, this study may establish the need for further 
funding to expand treatment capacity.  
The results of this study also offered newer evidence of Ohio’s substance abuse treatment 
infrastructure. A positive association was discovered between waivered provider densities and 
opioid overdose rates. This implies that given the higher disease burden in a county, more 
providers in that area likely obtained waivers to respond to the opioid burden in their county and 
expand capacity to provide treatment. Moreover, our results indicated that opioid treatment 
programs are more likely to be located in counties having the largest number of opioid related 
deaths. These results are consistent with national literature that documented a positive correlation 
between areas of greater treatment capacity and higher indicators of the opioid crisis18. Our study 
found that the average waivered provider density was 13.90 per 100,000 population. Other 
literature found national estimates for buprenorphine practitioner densities to be close to 14.3 per 
100,000 persons35. This estimate puts Ohio lower in provider supply compared to other states, 
which demonstrates sufficient room for improvement to expand the provider supply in Ohio.  
County-level variability was demonstrated within our results between treatment capacity 
and disease burdens. A moderate, positive relationship between waivered provider supply and 
overdose rates suggested providers in high burden counties were more likely to obtain a waiver. 
However, we found that in counties with the highest overdose rates, their provider densities did 
not rank top within Ohio. This likely indicates that providers did not locate where the highest 
needs are. This mismatch implies that having a high opioid burden may influence waivered 
providers to obtain waivers in their county, but it doesn’t strongly push providers to move and 
practice in these vulnerable regions. Therefore, this may demonstrate a potential shortage in 
MAT prescribers to address the high opioid mortality rates in these counties. Moreover, this 
study may reaffirm that each county has its own discrepant profile of overdose mortality and 
provider density. Substantial county-level maldistributions between the availability of 
buprenorphine providers and the burden of opioid overdose deaths have been witnessed on a 
national level in literature36. Therefore, it is important to consider other factors that may explain 
some of this incongruity between provider supply and deaths.  
Lastly, our results indicated that most waivered practitioners in Ohio were physicians, 
despite enactment of the 2016 Comprehensive Addiction and Recovery Act expanding 
prescribing capacity to include Nurse Practitioners and Physician Assistants.  
Across all counties, poverty rate had a weak, significant positive correlation with 
overdose opioid mortality rates. No significant difference in poverty rates were found between 
the highest and lowest overdose rate counties. However, this finding may have been limited to 
the effect of small sample sizes. Therefore, the significance of poverty rate in this study may 
imply that poverty slightly increases the risk of being a high overdose county. This is consistent 
to other literature demonstrating that opioid fatality is associated with factors of low 
socioeconomic status, including poverty37.  
The results of this study have implications for future policy. The lower supply of nurse 
practitioners and physician assistants as waivered providers suggests potential in expanding this 
supply of providers to provide medication assisted treatment. Evidence in other literature 
indicate that almost 37% of physician assistants and nurse practitioners report treating no 
patients38, and that sufficient time with patients and a lack of institutional support remains a 
concern for physicians39. Additional initiatives to encourage nurse practitioners and physician 
assistants to obtain a waiver may increase prescribing capacity among treatment programs and 
give additional time and support to both physicians and patients.  
Additionally, a medium correlation between waivered providers and opioid overdose 
mortality rates may represent that waivered providers don’t necessarily practice where patients 
are in the most need. This trend could help inform future city planners and health systems to 
place a higher emphasis on these high need regions when implementing new treatment programs 
and allocating funds. Moreover, the weak positive correlation between poverty rates and opioid 
deaths, along with county-level differences between burden of opioid deaths and waivered 
provider supply, demonstrate the presence of different mechanisms producing variabilities in 
opioid deaths. Each county seems to possess a different profile, and this variability should be 
accounted for by providers and hospital systems when focusing on population health. 
Community level initiatives to alleviate substance abuse should be differentiated in ways to best 
serve their counties, as there doesn’t seem to be a one size fits all approach.  
 
Limitations 
There are five limitations worth noting in this study. First, the SAMHSA buprenorphine 
practitioner database is the most comprehensive source publicly available, but it is not entirely 
complete. Some providers in the database don’t agree to make their information public in the 
database and are not necessarily included in the final list. This could potentially underestimate 
the supply of providers able to offer medication assisted treatment, and therefore, impact the total 
waivered provider densities for each of the counties.  
Second, the accuracy of the SAMHSA Provider database is another data limitation.  The 
missing values in provider type for some providers in the database is a challenge to describe 
provider demographics.  
Further, listed waivered providers do not warrant health care availability. In fact, earlier 
literature indicated that within a cohort of providers in the SAMHSA database who didn’t have 
appointments available, 32.9% could not be reached and 37.5% of the numbers were incorrect40. 
The extent of the inaccuracies within waivered providers in Ohio is unknown, though 
inconsistencies is likely to affect health outcomes, including mortality rates, if those are unable 
to receive care.  
An analysis of a cohort of providers within the SAMHSA database found that out of 505 
providers, 72.3% did not have appointments available40. The assumption that those who had 
waivers all prescribed treatment is also likely to complicate results. One survey of Ohio 
Specialty Treatment Organizations found almost 48.3% reported insufficient prescribing 
capacity26. Prescribing capacity may be due in part to the waiver restrictions on providers with 
prescribing capacities limiting the amount of prescriptions to 30, 100 or 275 patient limits per 
month. One study characterizing Ohio office-based physicians participating in office-based 
therapy found that nearly one in five of listed physicians are not active office-based therapy 
prescribers25. Therefore, a supply of providers as implicated within the database, doesn’t 
automatically translate to administering treatment.  
Moreover, individuals may also seek care within different counties. Thus, they may be 
counted apart of the population in counties that they don’t actually seek care. It is also likely that 
overdose death rates are underreported. Some researchers have found that as many as 70,000 
opioid overdose deaths were unreported or misclassified between 1999 to 2015 due to how these 
overdoses were reported on death certificates41. This may compromise the overall death rate in 
counties and the actual correlation with provider supply. 
Lastly, a supply of providers and treatment programs does not directly translate to a 
reduction in opioid overdose mortality. Many factors diverge in the pathway from treatment 
availability to health outcomes that were not extensively explored in this study. Even if an opioid 
treatment program is present in a county, barriers may deter those to seek care. Among a survey 
of waivered Ohio physicians practicing in office-based settings, one in two active prescribers did 
not accept insurance for office-based therapy25.  For patients never receiving treatment, primary 
reasons for not seeking help include unreadiness to stop using the drug (40%), health coverage 
and cost barriers (34%), job discrimination (12%), and fears of community opinions (11.6%)42. 
Even if patients successfully access treatment, attrition under buprenorphine is close to 50-60% 
around 12 months and 40-50% at six months. Methadone patients experience similar rates as 40-
60% have left within 12-14 months43. Not staying the course of treatment may exacerbate the 
chance of relapse and possible opioid related mortality. Therefore, even if there is an abundant 
supply of providers, addiction itself proves a huge challenge. For many individuals, the struggles 
related to stigma, making the step to asking for help, treatment compliance, social interactions, 
and stressful experiences may outweigh an abundant supply of resources and complicate the path 
to recovery, which all play a role in the variation seen between provider supply and opioid 
deaths.  
Conclusion 
Overall, there was a medium positive correlation between the provider densities and 
opioid overdose mortality rates within Ohio counties. This likely suggests that providers residing 
in high opioid mortality regions were more likely to obtain waivers. Though, the medium 
correlation may still suggest an inadequate workforce supply to respond to these high opioid 
burdens. The county-level variations between waivered providers and opioid burdens further 
demonstrates this. A strong positive relationship was identified between opioid treatment 
programs and the number of drug overdose deaths in counties. Evidence of this may indicate 
these programs do tend to locate to where high opioid burdens occur. Poverty rates had a weak 
positive correlation to opioid overdose mortality rates and did not significantly differ between 
counties with the highest and lowest overdose rates compared to all other counties. An overall 
moderate, positive relationship between waivered providers and poverty rates suggest that 
providers may be more likely to obtain a waiver in poorer regions. The average waivered 
provider density was 13.90 per 100,000, and only 34% of all counties contained opioid treatment 
programs. Additionally, although the Comprehensive Addiction and Recovery Act expanded 
prescribing capacity to include Nurse Practitioners and Physician Assistants, physicians still 







Figure 1: Distribution of Waivered Provider Types.  
 
 
The total sum of all waivered providers registered in the SAMHSA Buprenorphine Waiver 
database by provider type across all counties. 
 
Table 1: The Number of Providers Who Practiced in More Than One County with 
Waivers. 
Number of Counties Practiced At Number of providers who practiced in more than 
one county  
2 counties 42 
3 counties 6 
4 counties 1 















Provider type not reported
 
Figure 2: Distribution of Waivered Provider Density. 
 
The numbers in the brackets of the horizontal axis represent the waivered provider densities with a standard 
bin width of 8 waivered providers per 100,000 population. The numbers on top of the bars represent the 





















Figure 3: Correlation between Drug Overdose Mortality Rate and Total Waivered 





















Figure 4: Correlation Between Overdose Death Numbers and The Number of Opioid 











































Table 2: Waivered Provider and OTP Densities for Ohio Counties Having the Highest Overdose Rates. 
























1) Montgomery 70 16.9 26.11 10 13.52 7.33 1.31 1.31 
2) Clark 62 14.9 15.60 25 8.17 3.72 2.23 0.74 
3) Butler 60 12.4 14.65 28 8.11 5.75 0.78 0.78 
4) Trumbull 57 17.6 12.08 35 7.55 3.52 0.50 1.01 
              Brown 57 11.8 6.88 61 2.29 4.59 0.00 2.29 
5) Scioto 52 22.6 47.68 1 25.16 21.19 0.00 1.32 
*The waivered provider ranking assigns each county in order of the highest to lowest waivered provider densities. A score of 1 represents the highest 
density, and a score of 88 represents the lowest density.   
 
Table 3: Comparison Between the Provider Densities for Ohio Counties Having the Lowest Overdose Rates. 
Counties with 























1) Morgan 0 17 6.85 62 0 6.85 0 0 
2) Vinton 0 19 7.61 55 0 7.61 0 0 
3) Delaware 11 4.1 8.79 50 7.32 0.49 0.49 0 
4) Auglaize  12 6.9 6.55 64 2.18 2.18 2.18 0 
5) Putnam 13 5.5 8.89 49 5.92 2.96 0 0 
           Coshocton 13 15.4 8.19 52 5.46 2.73 0 0 
              Athens 13 30.7 19.75 16 13.67 4.56 0 1.52 
*The waivered provider ranking assigns each county in order of the highest to lowest waivered provider densities. A score of 1 represents the highest 
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